Table 3.

List of clinical trials using OVs in combination with immune checkpoint blockade therapies for various cancers.

Trial	Virus Type	OV Agent	ICB Therapy		Phase (s)	Cancer (s)
			Agent	Target
NCT03004183	Adenovirus	ADV/HSVtk	Pembrolizumab	PD-1	II	Metastatic NSCLC, Metastatic TNBC
NCT02798406	Adenovirus	DNX-2401	Pembrolizumab	PD-1	II	Glioblastoma, Gliosarcoma
NCT03003676	Adenovirus	ONCOS-102	Pembrolizumab	PD-1	I	Advanced/unresectable melanoma progressing after PD-1 blockade
NCT03408587	Coxsackie	CAVATAK	Ipilimumab	CTLA-4	Ib	Uveal Melanoma with Liver Metastases
NCT02565992	Coxsackie	CAVATAK	Pembrolizumab	PD-1	I	Advanced Melanoma
NCT02824965	Coxsackie	CAVATAK	Pembrolizumab	PD-1	I, II	Advanced NSCLC
NCT03153085	HSV	HF10 (TBI-1401)	Ipilimumab	CTLA-4	II	Unresectable/Metastatic Melanoma
NCT02272855	HSV	HF10 (TBI-1401)	Ipilimumab	CTLA-4	II	Unresectable/Metastatic Melanoma
NCT03259425	HSV	HF10 (TBI-1401)	Nivolumab	PD-1	II	Resectable Stage IIIB/C, IV Melanoma
NCT01740297	HSV	T-Vec	Ipilimumab	CTLA-4	Ib, II	Unresected Stage IIIb/IV melanoma
NCT02263508	HSV	T-Vec	Pembrolizumab	PD-1	Ib, III	Unresectable Stage IIIb/IV Melanoma
NCT02626000	HSV	T-Vec	Pembrolizumab	PD-1	Ib, III	Recurrent/Metastatic HNSCC
NCT02879760	Maraba Virus	MG1-MAGEA3	Pembrolizumab	PD-1	I, II	Previously treated NSCLC
NCT03206073	Vaccinia	Pexa Vec	Durvalumab	PD-L1	I, II	Refractory Colorectal Cancer
			Tremelimumab	CTLA-4
NCT02977156	Vaccinia	Pexa Vec	Ipilimumab	CTLA-4	I	Metastatic/Advanced Solid Tumors
NCT03071094	Vaccinia	Pexa Vec	Nivolumab	PD-1	I, IIa	Advanced HCC
NCT04185311	HSV	T-Vec	Ipilimumab	CTLA-4	I	Localized Breast Cancer
			Nivolumab	PD-1
NCT03889275	Newcastle disease virus	MEDI5395	Durvalumab	PD-L1	I	Advanced Solid Tumors
NCT04301011	Vaccinia	TBio-6517	Pembrolizumab	PD-1	I, II	Triple Negative Breast Cancer Microsatellite Stable Colorectal Cancer
NCT04735978	HSV	RP3	Anti-PD-1 mAb	PD-1	I	Advanced Solid Tumor
NCT04348916	HSV	ONCR-177	Pembrolizumab	PD-1	I	Advanced Solid Tumors
NCT03294083	Vaccinia	Pexa Vec	Cemiplimab	PD-1	I, II	Renal Cell Carcinoma
NCT04755543	HSV	OH2	LP002	PD-1	I	Digestive System Neoplasms
NCT04386967	HSV	OH2	Keytruda	PD-1	I, II	Solid Tumors, Melanoma
NCT04616443	HSV	OH2	HX008	PD-1	I, II	Melanoma
NCT03866525	HSV	OH2	HX008	PD-1	I, II	Solid Tumors, Gastrointestinal Cancer
NCT03206073	Vaccinia	Pexa-Vec	Durvalumab	PD-L1	I, II	Colorectal Neoplasms
			Tremelimumab	CTLA-4
NCT04665362	Alphavirus	M1	SHR-1210	PD-1	I	Advanced/Metastatic Hepatocellular Carcinoma
NCT04685499	Adenovirus	OBP-301	Pembrolizumab	PD-1	II	HNSCC